Holen Sie sich die Stockscreener-App
35.63
0.45%
0.16
Handel nachbörslich:
35.50
-0.13
-0.36%
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap - Sahm
Is Viking Therapeutics (VKTX) Price Move Justified By DCF And Book Value Signals - Yahoo Finance
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026 - Meyka
Jefferies reiterates Buy on Viking Therapeutic stock, $101 target - Investing.com
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback? - NAI500
WINTON GROUP Ltd Buys Shares of 68,700 Viking Therapeutics, Inc. $VKTX - MarketBeat
Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026 - The Motley Fool
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 - AOL.com
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
How Viking Therapeutics Inc. (VKTX) Affects Rotational Strategy Timing - Stock Traders Daily
Insider Buying: Neil Aubuchon Acquires Shares of Viking Therapeu - GuruFocus
Management Purchase Signals Confidence in Viking Therapeutics' Pipeline - AD HOC NEWS
Viking Therapeutics (NASDAQ:VKTX) Insider Acquires $149,912.50 in Stock - MarketBeat
Viking Therapeutics Stock Gets RS Rating Upgrade - Investor's Business Daily
Viking Therapeutics at Leerink Conference: Strategic Moves in Obesity Market - Investing.com
2 Under-the-Radar Stocks to Buy and Hold - AOL.com
VKTX: Rapid progress in dual agonist obesity trials sets up major data and commercial milestones for 2026 - TradingView
VKTX: Phase 3 obesity trials advance rapidly, with pivotal data and new oral options expected in 2026 - TradingView
Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in - Yahoo Finance
Top 10 Takeover Targets of 2026GEN - GEN - Genetic Engineering and Biotechnology News
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street - AOL.com
Viking Therapeutics, Inc. $VKTX Shares Purchased by Rhenman & Partners Asset Management AB - MarketBeat
Viking Therapeutics (VKTX) Valuation Check After Recent Share Price Swings And Analyst Fair Value Gap - Yahoo Finance
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Time To Reassess Viking Therapeutics (VKTX) After Its Recent Share Price Swings - simplywall.st
Assessing Viking Therapeutics (VKTX) Valuation After Sharp Swings And Obesity Drug Optimism - simplywall.st
Viking Therapeutics, Inc. (VKTX) Experiences a Steeper Decline Compared to the Overall Market: Important Takeaways - Bitget
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Notable Two Hundred Day Moving Average CrossVKTX - Nasdaq
Biotech Viking Therapeutics heads to twin Miami investor conferences - Stock Titan
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play - Stocktwits
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook - Finviz
VKTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring A 178% Upside Potential - DirectorsTalk Interviews
Viking Therapeutics (VKTX) Stock: Financial Performance Highlights 22% Revenue Growth and 44% Profit Increase in 2025 - MEXC
Viking Therapeutics, Inc. (VKTX) Stock: Revenue Surges 22% as Adjusted Net Income Jumps 44% in 2025 - MEXC
Rafferty Asset Management LLC Purchases 41,888 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Vanguard Group Reduces Stake in Viking Therapeutics - National Today
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
Viking Therapeutics, Inc. $VKTX Shares Sold by Vanguard Group Inc. - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Upgraded at BTIG Research - MarketBeat
Viking Therapeutics (VKTX) Is Up 9.1% After Advancing VK2735 As Rival Obesity Drug Stumbles - simplywall.st
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today - Yahoo Finance
Viking Therapeutics: The High-Stakes Weight Loss Contender - MarketBeat
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus - simplywall.st
Viking Therapeutics Gains Ground Amid Novo Nordisk's Clinical Setback - AD HOC NEWS
Is Viking Therapeutics (VKTX) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - The Motley Fool
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125 - 富途牛牛
Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st
Viking Therapeutics Gains Momentum as Rival Stumbles - AD HOC NEWS
Viking Therapeutics Shares Surge as Rival Stumbles in Obesity Drug Race - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Investor Outlook: A 169% Upside Potential Sparks Interest - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX): A bull case theory - MSN
Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com
Viking Therapeutics Gains Momentum in Competitive Weight-Loss Drug Arena - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Bitget
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):